通过CYP3A5药物遗传学来精制塔克罗利斯的剂量,在台湾的移植接受者中
Yen-Lin Chang1,2, Tzu-Hung Hsiao3,4,5, Yi-Ming Chen3,6,7,8,9
1Department of Pharmacy, Taichung Veterans General Hospital, Taichung, Taiwan.
Renal failure
|September 11, 2025
概括
在CYP3A5影响塔克罗利斯 (Tac) 水平的遗传变异. 通过基因型导向剂量确定低代谢者 (*3/*3) 可以显著减少移植患者的塔克罗利过度暴露.
科学领域:
- 药物基因组学 药物基因组学
- 移植医学 移植医学
- 临床药理学 临床药理学
背景情况:
- 在CYP3A5中的遗传多态性影响塔克罗利斯 (Tac) 的生物可用性.
- 塔克罗利斯的最佳基因型导向起始剂量仍未确定.
- 塔克罗利马斯是移植中重要的免疫抑制剂.
研究的目的:
- 为了研究CYP3A5基因型对台湾移植接受者的塔克罗利斯药理学的影响.
- 评估基因型导向剂量策略在预防塔克罗利斯过度暴露方面的有效性.
- 建立基于CYP3A5基因型的初始剂量公式.
主要方法:
- 对431名台湾脏移植接受者的回顾性队列研究.
- 用Axiom Genome-Wide TWB 2.0阵列进行的基因型鉴定.
- 在多个术后时间点分析塔克罗利斯剂量要求和血度.
主要成果:
- CYP3A5*3/*3载体 (代谢不良) 需要显著降低剂量,并且达克罗利斯过度暴露率最高 (34.14%).
- 一个基因型导向的初始剂量策略将塔克罗利斯过度暴露的可能性降低了69% (OR = 0.307,p = 0.018).
- 以后计算的剂量配方表明,在代谢较差的患者中,有降低剂量的潜力.
结论:
- 识别CYP3A5低代谢者 (*3/*3) 对于个性化塔克罗利斯治疗至关重要.
- 预防性药物遗传检测可以提高台湾患者的剂量精度和治疗安全性.
- 基因型导向的剂量策略在移植后最大限度地降低塔克罗利斯过度暴露风险方面表现有前途.
相关概念视频
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
211
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
211
01:11Renal Failure: Dose Adjustments
439
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
439
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
217
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
217
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195